Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAnthem formulary coverage & Prior Auth update | Op…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAnthemPolicy N/A

    Drug list — Five Tier Drug Plan (Formulary)

    Customize your policy alerts

    Sign up for all Anthem policy alerts

    Know when Anthem releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines the prescription drug list (formulary) structure, tiering, and basic member-facing rules for coverage, prior authorization, step therapy, quantity limits, and specialty distribution for Anthem members. Affects members and providers using the Anthem prescription benefit and pharmacy administrators.

    Policy Summary
    PayerAnthem
    PolicyDrug list — Five Tier Drug Plan (Formulary)
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes in this revision.
    Effective DateApr 1, 2026
    Next Review DateN/A
    Key ActionSubmit a prior authorization (PA) request when the formulary Notes column indicates PA before requesting coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    5formulary tiers (Tier 1–Tier 5)
    quarterlyupdate frequency of the drug list
    4/1/2026effective/current date stamp on extract
    PA; QL; LD; SPutilization controls noted
    PA / ST / QL / SP / DOcommon Notes codes

    Formulary Coverage Rules & Tiering

    Formulary coverage conditions

    Covered when ALL of the following are met:

    Tier assignment and member cost share: Drugs are assigned to tiers (1–5) based on clinical effectiveness, availability of OTC options, and relative cost; member cost share increases with higher tiers

    Tier definitions include distinctions such as Tier 1a/1b and specialty tiers

    Utilization management flags may apply: Coverage of a drug is subject to any utilization management indicated on the formulary line (e.g., Prior Authorization (PA), Step Therapy (ST), Quantity Limits (QL), Limited Distribution (LD), Specialty (SP), Dose Optimization (DO))

    See the Notes column on the formulary row for applicable restrictions and required administrative actions

    Prior authorization/Step therapy/Quantity limits: Many drugs require prior authorization (PA), step therapy (ST), or have quantity limits (QL) as noted on the formulary; lack of required PA or exceeding QL may result in denial of coverage
    Policy Summary
    PayerAnthem
    PolicyDrug list — Five Tier Drug Plan (Formulary)
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes in this revision.
    Effective DateApr 1, 2026
    Next Review DateN/A
    Key ActionSubmit a prior authorization (PA) request when the formulary Notes column indicates PA before requesting coverage.
    SourceLink
    On This Page
    Formulary Coverage Rules & TieringFormulary Note Codes & Coding EntriesAuthorization, Documentation & Denial RiskPolicy Background & ScopeKey Terms & AbbreviationsInitial Therapy — ADHD/Stimulant NotesStep Therapy Requirements & ExamplesQuantity Limits & ExamplesSpecialty Pharmacy, Infusion & Distribution Requirements

    Providers must submit PA requests or documentation per payer procedures when 'PA' is listed; follow step-therapy requirements where 'ST' is noted

    Drugs listed on the formulary may still be subject to your specific plan's benefit design. If a medicine is not included on a member's drug list, the member may be required to pay the full cost. Providers may request coverage review or prior authorization on a member's behalf by calling the Member Services number on the back of the member ID card or by submitting a prior authorization form; if approved, the member’s cost share will depend on their plan benefits.

    Within the provided excerpt there are no explicit statements that particular drugs are categorically excluded; the listings show tier assignments and Notes (for example, quantity limits or PA) for specific formulations (e.g., vancomycin and linezolid entries). Refer to each formulary row for tier and Notes details that govern coverage requirements.

    This excerpt does not contain any explicit coverage exclusions. The antineoplastic and biologic entries are presented with tiers and utilization notes (e.g., LD, PA, SP) but no blanket exclusion language is shown in the provided text.

    Some drugs appearing on the formulary may nevertheless not be covered depending on the member's benefit design; the document notes members and prescribers should confirm coverage and pursue prior authorization as needed. The excerpt does not include clinical 'Not Medically Necessary' criteria for denying coverage of specific drugs.

    No explicit 'Not Medically Necessary' (NMN) determinations or clinical NMN criteria are present in the excerpt. Utilization flags such as PA, LD, QL, and SP are used to document administrative requirements, but NMN language is not provided here.

    Formulary Note Codes & Coding Entries

    Formulary note codesmixed
    PAprior authorization
    STstep therapy
    QLquantity limits
    SPspecialty drugs / specialty pharmacy
    DOdose optimization
    ALage limits
    BEbenefit exclusion
    Notes shorthand (aliases)mixed
    $0preventive drugs / $0 cost share
    LDlimited distribution
    Formulary drug formulations (no billing codes provided)NDC
    NDC not providedMultiple vancomycin intravenous and oral formulations listed with tier assignments (e.g., VANCOMYCIN HCL IN NACL INTRAVENOUS SOLUTION 1000 MG/200ML; vancomycin hcl intravenous solution reconstituted 1 gm, 2 gm, 5 gm, etc.; vancomycin hcl oral capsule; vancomycin hcl oral solution reconstituted 25 mg/ml; VANCOMYCIN HCL ORAL SOLUTION RECONSTITUTED 250 MG/5ML) — NDC values not provided in this excerpt.
    Additional drug listingsmixed
    Linezolid (IV and oral), aztreonam, EMBLAVEO, CAYSTON, polymyxins, colistimethate, SIVEXTRO, ORLYNVAH, BLUJEPA and other listed agents — presented without procedure/diagnosis or billing codes in this excerpt.
    No explicit billing/CPT/HCPCS/NDC codes in this excerptmixed
    No codes listed

    Authorization, Documentation & Denial Risk

    Prior Authorization

    Prior authorization required when 'PA' listed

    Prior authorization (PA) is required when the formulary Notes field lists “PA.” Review the Notes column for every drug entry — if “PA” appears the provider must obtain prior authorization before the drug will be covered.

    • How to request PA: Call the Member Services number on the member ID card or submit a prior authorization form via the plan website.
    • Formulary entries include drug name, strength, tier assignment and a Notes field that indicates utilization controls such as PA, QL (quantity limit), LD (limited distribution), SP (specialty), ST (step therapy), DO (dispense as written) or AL (site-of-care/administration limits).
    Prior Authorization

    Prior authorization required for many agents

    Many agents across formulary sections require prior authorization — including commonly used classes and specific high‑cost products. Failure to obtain PA may result in claim denial or member full cost responsibility.

    • Examples of products and classes requiring PA: simvastatin 80 mg; certain testosterone formulations (DEPO‑TESTOSTERONE, JATENZO, NATESTO, XYOSTED); selected specialty biologics (FASENRA, NUCALA, TEZSPIRE); PCSK9 and other specialty injectables (e.g., some ORENCIA and ENBREL presentations).
    • Antineoplastics and many IV/injectable oncology agents are frequently labeled PA; LD; SP and require advance authorization and designated distribution channels.
    Prior Authorization

    PA for incretin/GLP‑1 agents

    Incretin / GLP‑1 receptor agonists and related agents are subject to prior authorization and often quantity limits; providers should submit PA documentation before dispensing.

    • Common examples flagged PA and QL: OZEMPIC (all strengths), RYBELSUS, TRULICITY, and liraglutide pen‑injectors.
    • Some combination products and incretin combinations (e.g., TRIJARDY XR, GLYXAMBI) may also have step‑therapy (ST) and QL requirements — verify Notes for each formulation.
    Prior Authorization

    Prior authorization required for listed specialty / high‑tier agents

    Certain listed specialty or high‑tier agents require PA and may also have limited distribution, quantity limits, or specialty pharmacy requirements. Submit supporting clinical documentation with PA requests.

    • Examples: OTEZLA XR, ORENCIA (ClickJect, Prefilled), ENBREL presentations, FASENRA, NUCALA, TEZSPIRE — Notes include PA; LD; QL; SP.
    • Providers should include clinical rationale, prior therapy history (for ST), and dosing plan when requesting PA for specialty agents.
    Prior Authorization

    Prior authorization and utilization controls for antineoplastics and LD/SP products

    Prior authorization and utilization controls apply to many antineoplastic and other limited‑distribution products; follow site‑of‑care and specialty distribution instructions when present.

    • Antineoplastics commonly annotated with PA; LD; QL; SP — examples: ADCETRIS, MYLOTARG, DARZALEX, POLIVY, IMJUDO, YERVOY, LYNPARZA, RUBRACA, ZEJULA.
    • Authorization requests should specify intended site of care, dosing, and whether product requires limited distribution or specialty pharmacy dispensing.
    Prior Authorization

    Prior authorization required for specific products

    Some specific products explicitly require PA — ensure the PA is obtained and documentation accompanies the request to avoid denial.

    • Cardiovascular and lipid examples: JUXTAPID (PA; LD; QL), TRYVIO (PA; QL).
    • Antimicrobials / others: certain oral or IV formulations may list PA (see cefazolin reconstituted examples below).
    Prior Authorization

    Prior authorization for select reconstituted cefazolin formulations

    Certain reconstituted cefazolin/dextrose intravenous solutions have PA on specific formulations — verify the exact NDC/format before administration and submit PA when noted.

    • Examples: cefazolin sodium‑dextrose IV solution reconstituted 3‑2 gm‑%(50ml) is noted with PA in the formulary excerpt.
    • When reconstituted or pre‑mixed IV formulations have PA, include indication, expected dose/volume, and anticipated duration in the authorization request.
    Prior Authorization

    Prior authorization required for selected biologics and specialty agents

    For biologic and specialty injectable agents, Notes frequently include PA and SP/LD designations. Use required specialty channels and include distribution documentation with PA submissions.

    • Examples: SIMPONI ARIA, ENBREL, ORENCIA, REPATHA, FASENRA, NUCALA — many presentations are annotated PA; QL; SP; LD.
    • Some biologics additionally include site‑of‑care or administration limits (AL) or require use of a specialty pharmacy — follow plan instructions to avoid denial.
    Prior Authorization

    Higher‑tier IV agents — PA and medical review risk

    Higher‑tier IV agents and many injectables may trigger medical review, PA, and specialty distribution requirements; include infusion site and dispensing details in PA documentation.

    • Examples: Many IV antineoplastics and high‑cost injectables (e.g., ADMIRAL‑class agents, select carbapenems/vancomycin IV presentations) show PA; LD; SP or QL.
    • Claims for higher‑tier IV agents without the required PA or LD/SP billing information risk denial or retrospective audit.
    Denial Risk

    Quantity limits and limited distribution denial risk

    Quantity limits (QL) and limited distribution (LD) flags are common; exceeding QL or using non‑designated distribution channels can cause denial even when PA is present.

    • If Notes show QL, ensure the requested quantity/days‑supply is within the limit or justify medical necessity in the PA.
    • For LD products, only approved distributors or specialty pharmacies may supply the drug — include distributor information on the PA to prevent delays.
    Denial Risk

    Program‑based denial triggers and non‑formulary risk

    Program‑based denial triggers include unmet PA, missing step‑therapy (ST) requirements, surpassing QL, incorrect dispensing channel for LD/SP products, or absence of required documentation.

    • Common UM flags: PA, ST, QL, LD, SP, DO, AL — include these codes with claims or PA submissions.
    • If a drug is not on the formulary (non‑formulary), the member may be responsible for full cost unless PA/exception is approved; providers should advise members and consider therapeutic alternatives covered by the plan.
    Step Therapy

    Step therapy requirements present

    Step therapy (ST) indicators are present for numerous combination products and classes. When ST is indicated in Notes, prior trials of preferred medications must be documented in the PA.

    • Examples: TRIJARDY XR, GLYXAMBI and several metformin combinations show ST; many stimulant/transdermal methylphenidate products include ST annotations for select formulations.
    • Document prior therapies, reasons for failure or intolerance, and dates when submitting ST‑related PA requests.
    Documentation Required

    Documentation for PA submissions

    Documentation is required to support PA requests. Include clinical rationale, prior medication trials (for ST), dosing plan, expected duration, site of care, and distributor/specialty pharmacy details where applicable.

    • Use the plan’s PA form or the Member Services contact to submit requests.
    • Attach clinical notes, prior lab/imaging if relevant, and any specialty pharmacy acceptance or limited distribution agreements to the PA submission.

    Policy Background & Scope

    The formulary is a managed list of FDA‑approved brand and generic prescription drugs maintained through a Pharmacy & Therapeutics (P&T) committee. The committee evaluates safety, effectiveness, and value when assigning drugs to tiers and when applying utilization management controls such as prior authorization, step therapy, quantity limits, and specialty distribution.

    Key Terms & Abbreviations

    Formulary definition / Drug list / Formulary
    DefinitionFormulary (drug list): a list of prescription medicines covered by the plan.
    ScopeIncludes FDA‑approved brand and generic prescription drugs organized by therapeutic class and assigned to tiers 1–5.
    PurposeShows tier assignments, notes (PA, QL, LD, SP, ST, DO, AL, BE) and any utilization controls that affect coverage and member cost share.
    Notes codes mapping
    PAPrior Authorization
    STStep Therapy
    QLQuantity Limit
    SPSpecialty (specialty drugs / specialty pharmacy)
    DODose Optimization
    ALAge Limits
    BEBenefit Exclusion (drug may not be covered depending on plan design)
    PA definition — Prior authorization
    TermPrior Authorization (PA) — approval required before coverage for certain prescriptions.
    IndicatorPA appears in the formulary Notes column to show where preapproval is required.
    ActionProviders must submit PA per payer procedures (call Member Services or submit PA form) when Notes = PA.
    QL definition — Quantity limit
    DefinitionQuantity Limit (QL) — limits on the amount of medicine covered within a specified time period.
    ManifestationQL appears in the Notes column on formulary rows to indicate product‑specific limits (e.g., stimulants, antivirals, selected antipsychotics).
    ConsequenceClaims exceeding QL may be denied unless authorized or justified per plan rules.
    LD definition — Limited distribution
    DefinitionLimited Distribution (LD) — product may be available only through designated channels or specific distributors.
    UsageLD is noted in the Notes column for products requiring restricted sourcing (common among certain oncology and specialty agents).
    Provider implicationProviders must obtain medication from the specified channel or documentation may be required for processing.
    Notes shorthand — common Notes seen on the formulary
    PAPrior Authorization
    QLQuantity Limit
    LDLimited Distribution
    SPSpecialty (specialty pharmacy / site-of-care)
    LD = Limited Distribution
    AcronymLD = Limited Distribution
    ContextUsed on formulary rows to denote restricted distribution channels for specific products.
    ExamplesAppears on specialty or certain oncology agents (see Notes entries).
    Utilization management abbreviations
    QLQuantity Limit — maximum allowed quantity over a time period.
    PAPrior Authorization — approval required before coverage.
    STStep Therapy — member must try another recommended drug first.
    SPSpecialty — specialty pharmacy or site-of-care requirement.
    PA (definition repeated)
    DefinitionPA — Prior authorization required before coverage is provided for the listed drug.
    IndicatorMarked as 'PA' in the formulary Notes column for specific products (e.g., many biologics, selected specialty agents).
    Provider actionSubmit PA documentation per payer instructions when Notes = PA to avoid denial.
    QL (definition repeated)
    DefinitionQL — Quantity limits indicating product‑specific maximums (amount per month/course).
    ExamplesUsed for stimulants, select antivirals, and other products noted with 'QL' on formulary rows.
    ConsequenceClaims exceeding the QL may require prior approval or may be denied.
    LD (definition repeated)
    DefinitionLD — Limited Distribution; product available only through designated channels or distributors.
    Common useFrequently applied to oncology and specialty biologic agents (Notes show 'LD').
    Provider implicationUse designated channel/specialty pharmacy as required by plan to obtain product coverage.
    SP (definition repeated)
    DefinitionSP — Specialty (specialty pharmacy or site-of-care).
    PurposeIndicates specialty handling or that the product may require dispensing via a specialty pharmacy or specific site of care.
    ExamplesAppears on biologics and complex therapies (e.g., FASENRA, NUCALA, ENBREL entries).
    ST (definition repeated)
    DefinitionST — Step Therapy; member may need to try a recommended alternative drug first before the requested drug is covered.
    IndicatorShown as 'ST' in the Notes column for applicable products (e.g., some psychiatric and metabolic agents).
    Provider actionDocument prior trials of preferred agents when submitting for coverage if Notes = ST.
    Abbreviations used in Notes — summary mapping
    SummaryPA = Prior Authorization; QL = Quantity Limit; LD = Limited Distribution; SP = Specialty; ST = Step Therapy; DO = Dose Optimization; AL = Age Limits; BE = Benefit Exclusion.
    UsageThese abbreviations appear in the Notes column of formulary rows to indicate utilization controls and administrative requirements.
    ActionProviders and pharmacies should check the specific formulary line for Notes to determine required documentation or channels.
    Prior Authorization (short tag) - duplicate
    PAPA — Prior Authorization (short tag used in Notes).
    QLQL — Quantity Limit (short tag used in Notes).
    LDLD — Limited Distribution (short tag used in Notes).
    Limited Distribution (short tag) - duplicate
    LDLD — Limited Distribution (short tag).
    NoteUsed to denote products available only through specified channels.
    ExamplesCommon for certain antineoplastics and specialty injectables (see LD notes).
    Quantity Limit (short tag) - duplicate
    QLQL — Quantity Limit (short tag).
    NoteIndicates maximum allowed quantity per time period or course when present on formulary lines.
    ExamplesSeen on many stimulant entries and antiviral / influenza agents (Notes = QL).
    Specialty Pharmacy or Site‑of‑Care (short tag) - duplicate
    SPSP — Specialty Pharmacy or Site‑of‑Care (short tag).
    NoteIndicates specialty dispensing or site requirements; commonly paired with PA/LD/QL on biologics and oncology agents.
    Provider actionFollow plan instructions for specialty pharmacy use when SP is listed.
    PA (definition repeated)
    PAPrior Authorization — approval required before coverage for certain drugs when 'PA' appears in Notes.
    How it's shownDisplayed as 'PA' in the Notes column on formulary lines (many specialty and high‑tier agents).
    ActionProviders must submit PA per payer instructions; absence of PA may lead to denial.
    QL (definition repeated)
    QLQL — Quantity Limit denotes product‑specific maximum quantities; appears in Notes for numerous products.
    ExamplesApplied to stimulants, topiramate ER, Ozempic/Rybelsus/Trulicity and many antiviral agents as noted.
    Provider implicationClaims exceeding QL may require PA or may be denied if limits are not met.
    LD (definition repeated)
    LDLD — Limited Distribution; indicates restricted sourcing channel for a product.
    Typical usesCommon for select antineoplastics, injectables, and specialty therapies (Notes show 'LD').
    Operational noteProviders must use the specified distribution channel or provide sourcing documentation as required.
    Tier notation explanation
    ExplanationTier notation (e.g., '1 or 1a*', 'Tier = 3') denotes formulary tier assignments used for member cost‑sharing and preferred status.
    GuidanceRefer to the specific formulary row for tier details and any sub‑tier distinctions (1a/1b) shown in the listing.
    ImplicationTier determines member cost share and placement of therapeutically similar agents in preferred subgroups.

    Initial Therapy — ADHD/Stimulant Notes

    ADHD / stimulant initial therapy notes

    Formulary notes and utilization controls for ADHD and stimulant agents:

    PA and QL notes for stimulants: Multiple stimulant products (including amphetamine/dextroamphetamine, dextroamphetamine, lisdexamfetamine, methylphenidate and related ER formulations) are listed on the formulary with Notes indicating Prior Authorization (PA), Quantity Limits (QL), and/or Dose Optimization (DO) depending on formulation and strength

    Specific strengths and the exact Notes (PA; QL; DO) are shown on each formulary line and must be referenced when requesting authorization

    Step therapy applicability: Certain stimulant formulations (for example, specific chewable methylphenidate tablets and transdermal methylphenidate patches) may carry 'ST' (step therapy) or other sequencing requirements on the formulary

    Where 'ST' appears in Notes the prescriber must document trials of preferred agents per plan rules before coverage

    Provider actions for ADHD/stimulant coverage: When formulary Notes include PA, QL, or ST for a stimulant product, providers must submit prior authorization requests and supporting documentation or adhere to step therapy and quantity limit rules to obtain coverage

    Failure to meet PA, ST, or QL requirements may result in claim denial or member liability

    Step Therapy Requirements & Examples

    Coverage itemNotes / implication
    Formulary entries annotated 'ST' (step therapy)
    Indicates member must try specified preferred or lower‑cost agent(s) before the listed drug will be approved (ST flag shown in Notes column)
    Product / formulationNotes (ST presence) / implication
    Methylphenidate HCl oral tablet chewable (2.5 mg)
    Notes = ST; DO (chewable 2.5 mg shows ST indicating step therapy applies for this formulation)
    Methylphenidate transdermal patch (10 mg/9hr, 15 mg/9hr; 20 mg/9hr, 30 mg/9hr)
    Notes = ST on several transdermal strengths (patch entries list ST and/or QL), indicating step therapy requirements for transdermal formulations
    Biologic / specialty agent examplesNotes (ST / SP / tiering implications)
    OTEZLA XR (oral extended‑release)
    Notes = PA; QL; SP — annotated SP and PA; some biologics/specialty agents are also annotated ST in formulary indicating step/specialty sequencing may apply
    FASENRA / NUCALA (subcutaneous biologics)
    Notes = PA; LD; QL; SP — specialty distribution and utilization controls; '1 or 1b*' tier notations used elsewhere to indicate subgroup placement which may affect sequencing
    Biologic agentUM flags / step therapy examples
    FASENRA subcutaneous solution (prefilled)
    Notes = PA; LD; QL; SP — prior authorization and specialty/limited distribution; step therapy specifics not provided in excerpt but SP/LD flags imply additional controls
    HERZUMA / KANJINTI / MARGENZA (IV oncology/biologic agents)
    Notes include PA; LD; SP and in some entries ST — product lines show PA/LD/SP with occasional ST annotations indicating step/specialty sequencing may apply
    Diabetes combination productNotes (ST presence) / implication
    Metformin HCl ER tablets and metformin-containing combinations
    Multiple metformin entries list Notes = ST; QL indicating step therapy and quantity limits apply for select formulations
    TRIJARDY XR (oral extended‑release)
    Notes = ST; QL — TRIJARDY XR is explicitly listed with ST
    GLYXAMBI (oral tablet)
    Notes = ST; QL — Glyxambi listed with ST indicating step therapy requirement
    Coverage itemNotes / provider implication
    Step therapy applies to multiple combination diabetes products (e.g., Trijardy XR, Glyxambi, dapagliflozin combinations)
    Notes include ST; QL — documentation of prior trials or prior therapy may be required when ST is indicated
    Product / groupNotes (ST presence) / implication
    Ezetimibe‑simvastatin and select statin formulations (examples in statin/PCSK9 sections)
    Formulary notes include ST or QL for some statin entries (e.g., certain strengths or formulations flagged ST), indicating step therapy requirements for products marked ST
    ProductNotes (ST presence)
    TREXALL (methotrexate) entry
    Notes include ST for this entry indicating step therapy may apply
    Product / entryNotes (ST presence) / implication
    Selected IV biologics and specialty agents (HERZUMA, KANJINTI, OGIVRI etc.)
    Notes include ST on some entries and PA/LD/SP on many — when ST is present step therapy rules apply; PA/LD/SP indicate additional site/distribution controls
    Product / groupNotes / implication
    Cefazolin sodium intravenous solutions and cephalosporin subgroup entries
    Some rows include equivalency annotations (e.g., '1 or 1b*') and other Notes but explicit step‑therapy algorithms are not provided in excerpt
    Product / exampleNotes (ST presence) / implication
    Various psychiatric agents and therapy packs (e.g., FANAPT titration packs, paliperidone, aripiprazole kits)
    Multiple therapy packs and some oral/IM products are noted with ST — trial of preferred agents per step therapy must be followed when ST is present
    Product / exampleNotes (ST presence) / implication
    ABILIFY MYCITE maintenance and starter kits; thiothixene and related antipsychotics
    Notes = ST on listed Abilify MyCite therapy packs and other antipsychotic entries — coverage requires adherence to step therapy protocols where ST is indicated
    Product / entryNotes (ST presence) / implication
    Various cardiovascular and antihypertensive entries (selected formulations)
    Some rows include Notes = ST; where ST appears the formulary requires following the step therapy sequence before coverage will be approved
    Formulary subgroup labelMeaning / implication for step/coverage sequencing
    '1 or 1b*' and equivalent subgroup annotations (seen in cephalosporin and other groupings)
    Indicates preferred subgroup placement or equivalency among agents; these subgroup labels inform tiering and may affect step/coverage sequencing though explicit step algorithms are not shown in this excerpt

    Quantity Limits & Examples

    QL indicated on specific formulary rows — ADHD/stimulant related
    ProductsVarious stimulant formulations (amphetamine/dextroamphetamine, dextroamphetamine ER, lisdexamfetamine, methylphenidate) are listed with Notes indicating PA, QL, DO depending on strength and form.
    Notes usageMany stimulant rows include 'PA' and/or 'QL' in the Notes column; some include 'DO' for dose optimization.
    ActionProviders should check the specific stimulant formulary line for required PA or quantity limits before prescribing/dispensing.
    Multiple stimulant products — QL indicated in Notes
    Multiple entriesMultiple stimulant products (various ER, IR, solution, chewable, transdermal forms) show Notes = PA and/or QL across strength/formulation variants.
    ExamplesEntries for amphetamine‑dextroamphetamine, dextroamphetamine sulfate (ER and IR), and lisdexamfetamine show PA; QL or PA; DO depending on strengths.
    Provider implicationCoverage for stimulant strengths/forms may vary; verify the exact formulary row when requesting PA or filling claims.
    OTEZLA XR ORAL TABLET EXTENDED RELEASE 24 HOUR — QL context
    ProductOTEZLA XR ORAL TABLET EXTENDED RELEASE 24 HOUR
    NotesNotes = PA; QL; SP (prior authorization, quantity limit, specialty pharmacy).
    TierTier = 4
    ENBREL (various presentations) — QL/PA context
    ProductENBREL (various presentations) — ENBREL SUBCUTANEOUS SOLUTION, ENBREL MINI, ENBREL SURECLICK
    NotesNotes = PA; QL; SP for multiple ENBREL presentations.
    TierTier = 4
    Multiple entries with Notes = QL
    ObservationMultiple formulary entries are annotated with Notes = QL indicating quantity limits across classes and products.
    ImplicationWhere 'Notes = QL' appears, claims are subject to the stated quantity restrictions and may require authorization if exceeded.
    ActionCheck each formulary line for product‑specific QL details when prescribing or dispensing.
    ZTALMY ORAL SUSPENSION — QL
    ProductZTALMY ORAL SUSPENSION
    NotesNotes = LD; QL (limited distribution and quantity limit).
    TierTier = 5
    MOUNJARO, OZEMPIC, RYBELSUS, TRULICITY — PA; QL examples
    ProductsMOUNJARO, OZEMPIC, RYBELSUS, TRULICITY
    NotesNotes = PA; QL for these incretin/GLP‑1 agents (prior authorization and quantity limits).
    TierTypically Tier = 2 for listed presentations (verify specific row).
    Naloxone (various formulations) — QL noted where specified
    Product classNaloxone and other naloxone formulations show QL where specified in Notes.
    ExamplesVarious naloxone formulations are listed with Notes = QL in applicable rows.
    ActionPharmacies should apply the QL when adjudicating naloxone claims per formulary guidance.
    Various formulation-specific QL entries
    ObservationMultiple formulation‑specific entries across antihistamines/statins and other classes include QL flags in Notes.
    Exampleslevocetirizine oral solution and certain atorvastatin strengths show BE; QL or QL notes respectively.
    Provider implicationConfirm the exact formulation row to determine if a QL applies.
    Linezolid oral suspension/tablet — QL indicated
    ProductLinezolid (oral suspension and oral tablet)
    NotesNotes = PA; QL for oral suspension and oral tablet presentations (PA and quantity limit indicated for oral forms).
    TierTier assignments vary by formulation; see specific formulary row.
    CAYSTON — LD; QL; SP indicated
    ProductCAYSTON (aztreonam for inhalation)
    NotesNotes = LD; QL; SP (limited distribution; quantity limit; specialty pharmacy).
    TierTier = 5 for inhalation solution presentation.
    BRAFTOVI ORAL CAPSULE 75 MG — QL context
    ProductBRAFTOVI ORAL CAPSULE 75 MG
    NotesNotes = PA; LD; QL; SP are indicated for some antineoplastic agents in this subgroup.
    TierTier = 3 (verify specific row).
    VENCLEXTA ORAL TABLET / STARTING PACK — QL context
    ProductVENCLEXTA ORAL TABLET / STARTING PACK
    NotesNotes = PA; LD; QL for Venclexta and starting pack presentations.
    TierTier = 3 for listed presentations.
    XPOVIO therapy packs — dosing variants / QL implications
    ProductXPOVIO therapy packs (various dosing schedules)
    NotesNotes = PA; LD; QL for multiple XPOVIO dosing schedules; therapy pack dosing variants are listed (QL implications).
    TierTier = 3 for listed therapy packs.
    LEUCOVORIN — QL noted for some oral presentations
    ProductLEUCOVORIN (various formulations)
    NotesSome oral tablet presentations show QL noted in the formulary rows.
    UseQL applies to specified formulations; check the exact row for limits.
    LYNPARZA; RUBRACA; TALZENNA; ZEJULA — Subject to QL per Notes
    ProductsLYNPARZA; RUBRACA; TALZENNA; ZEJULA
    NotesNotes = PA; LD; QL; SP for these PARP inhibitors (subject to quantity limits per formulary Notes).
    TierTier = 3 for the listed oral PARP inhibitors.
    VYALEV SUBCUTANEOUS SOLUTION 12-240 — QL noted
    ProductVYALEV SUBCUTANEOUS SOLUTION 12-240
    NotesNotes = PA; LD; QL; SP and additional Notes = DO; AL for some rows (indicates QL and other restrictions).
    TierTier = 3
    Multiple QL entries across section — see 'QL' note per product
    ObservationMultiple entries across the formulary include 'QL' in the Notes column — see product‑specific rows for exact limits.
    ScopeQL flags appear across stimulant, antiviral, antipsychotic, oncology, and other therapeutic sections.
    ActionConfirm the specific formulary line to determine the applicable quantity limit before prescribing or dispensing.
    Antiviral/antiviral agents — QL indicated
    Productsvalacyclovir, oseltamivir, RELENZA, XOFLUZA and other antiviral/flu agents
    NotesSeveral influenza and antiviral products are annotated with Notes = QL on formulary rows.
    Provider implicationPharmacies should apply QL when adjudicating antiviral prescriptions per the formulary Notes.

    Specialty Pharmacy, Infusion & Distribution Requirements

    Billing Rule

    Specialty pharmacy required when Notes = SP

    Agents marked 'SP' indicate specialty pharmacy dispensing may be required; providers must arrange specialty pharmacy enrollment and use the designated specialty channel when SP is noted.

    Billing Rule

    Follow site‑of‑care notes for IV biologics (infusion center / hospital outpatient / office)

    Some IV biologics and infusion products list site‑of‑care designations (infusion center, hospital outpatient, office); providers must follow the plan‑directed site‑of‑care instructions for administration.

    Documentation Required

    SP flag summary — comply with specialty pharmacy/site‑of‑care restrictions

    Multiple agents are flagged SP across the formulary indicating specialty pharmacy or site‑of‑care restrictions; providers must comply with specialty dispensing requirements for SP‑flagged drugs.

    Billing Rule

    Infusion center/hospital outpatient administration expected for many IV agents

    Many IV/infusion formulations are typically administered in infusion centers or hospital outpatient settings; providers should arrange administration in the appropriate site‑of‑care as indicated.

    Billing Rule

    LD/SP notes imply restricted dispensing or site requirements (e.g., PREVYMIS, TROGARZO)

    Some specialty or infused agents include LD or SP notes implying restricted dispensing or site requirements (examples include IV PREVYMIS and TROGARZO); providers must use designated distribution channels and sites for these agents.